Volume 15, Issue 2, February 2010

The author comments on the findings of Mantovani et al. with combination therapy to treat cancer cachexia published in this issue of The Oncologist.

Reported are results from a subgroup analysis of postmenopausal women with hormone receptor–positive human epidermal growth factor receptor 2–positive metastatic breast cancer from a phase III trial of letrozole plus placebo versus letrozole plus lapatinib. The combination was well tolerated and more efficacious than letrozole alone.

This review focuses on the potential cardiovascular toxicities associated with the use of bevacizumab, sunitinib, and sorafenib in order to increase awareness about these complications and to discuss their clinical significance and therapeutic interventions.

The paper reports on the coadministration of highly effective antiretroviral therapy and sorafenib for hepatocellular carcinoma in a patient coinfected with HIV and hepatitis C virus. The simultaneous administration of these therapies was well tolerated and effective.

This review discusses both traditional and novel treatments for metastatic differentiated thyroid cancer with a particular focus on emerging treatments for patients with radioactive iodine–refractory disease.

This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.

This review discusses the current status and key issues involved in the management of gallbladder cancer.

This review explores the potential basis for the failure of imatinib to cure chronic myeloid leukemia.

The article reviews the currently available treatment options for patients with limited-stage small cell lung cancer.

The manuscript examines the role of isocitrate dehydrogenase 1 and the IDH1 gene in the prognosis and therapy of glial tumors.

The authors report the results of a phase III clinical trial comparing five different treatment regimens in patients with cancer cachexia. Combination treatment with medroxyprogesterone or megestrol acetate, oral supplementation with eicosapentaenoic acid, L-carnitine, and thalidomide was most effective in these patients.

The article reports on the efficacy of sunitinib for thyroid carcinoma from a phase II trial.

The author responds to comments on the study published by Ravaud et al. in The Oncologist on sunitinib for medullary thyroid carcinoma.